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https://doi.org/10.1016/j.stemcr.2020.07.008Hematopoietic stem cell transplantation (HSCT) is a critical
treatment modality for many hematological and non-hemato-
logical diseases that is being extended to treat older individuals.
However, recent studies show that clonal hematopoiesis of inde-
terminate potential (CHIP), a common, asymptomatic condi-
tion characterized by the expansion of age-acquired somatic
mutations in blood cell lineages, may be a risk factor for the
development of donor-derived leukemia (DDL), unexplained cy-
topenias, and chronic graft-versus-host disease. CHIP may
contribute to the pathogenesis of these significant transplant
complications via various cell-autonomous and non-cell-auton-
omous mechanisms, and the clinical presentation of DDL may
be broader than anticipated. A more comprehensive under-
standing of the contributions of CHIP to DDL may have impor-
tant implications for the screening of donors and will improve
the safety of HSCT. The objective of this review is to discuss
studies linking DDL and CHIP and to explore potential mecha-
nisms by which CHIP may contribute to DDL.Introduction
Hematopoietic stem cell transplantation (HSCT) is an
important treatment option for a variety of malignant
and non-malignant hematological and non-hematologi-
cal diseases. In autologous transplantation, bone
marrow (BM) from a patient is harvested before myeloa-
blation and is then re-infused into the same patient. In
contrast, allogeneic transplantation replaces the recipi-
ent’s BM with donor BM after myeloablation. A key
feature of HSCT is its reliance on the ability of hemato-
poietic stem and progenitor cells (HSPCs) to reconstitute
the BM and to undergo normal hematopoiesis. Despite
the utility of HSCT, a variety of complications can
occur, including infection, secondary malignancy, and
relapse (Hatzimichael and Tuthill, 2010). Originally pio-
neered in children, HSCT is now being used in older pa-
tient populations (Muffly et al., 2017). However, the
incidence of relapse in elderly patients undergoing allo-
geneic HSCT is 35–40% after 1–2 years, inferring that
relapse may be a significant concern (Hsu et al., 2020).
While the extension of HSCT to older patient popula-
tions offers a valuable new treatment option, it is
important to understand the risk factors that may influ-
ence transplant outcomes in this population.Stem Cell Re
This is an open access article under the CDonor-derived leukemia (DDL) is a severe complication
of HSCT in which patients later develop a secondary leu-
kemia of donor origin (Fialkow et al., 1971; Wiseman,
2011). Previously considered rare, DDL mayconstitute
5% or more of leukemia relapses, and the number of cases
has continued to increase over the last 50 years, particu-
larly since 2000 (Suarez-Gonzalez et al., 2018a; Wiseman,
2011). The median age of recipients with DDL ranges
from 31 to 53 years, indicating that it may be more com-
mon in adults (Suarez-Gonzalez et al., 2018a; Wang et al.,
2011; Wiseman, 2011). DDL is distinguished from tradi-
tional relapse as it frequently exhibits different cytoge-
netic and phenotypic characteristics from the original dis-
ease, leading to considerable disease heterogeneity. Acute
myeloid leukemia (AML) accounts for about 50% of cases,
while acute lymphoid leukemia (ALL) and myelodysplas-
tic syndrome (MDS) represent 23% and 20% of cases,
respectively (Suarez-Gonzalez et al., 2018a; Wang et al.,
2011; Wiseman, 2011). Notably, while traditional relapses
present shortly after HSCT, DDL often exhibits a longer la-
tency with a median time to diagnosis of 26 months,
implying that significant changes must occur to promote
DDL (Suarez-Gonzalez et al., 2018a; Wiseman, 2011). The
heterogeneity of DDL and its origin from donor cells pro-
vide diagnostic and treatment challenges, and DDL pa-
tients often exhibit poor prognoses (Wiseman, 2011).
Mortality has been estimated at 47% within a median
follow-up period of 8.5 months, and the median time
from diagnosis to death is 10.6 months, underscoring
the importance of elucidating the causative factors of
DDL and of developing effective therapies (Suarez-Gonza-
lez et al., 2018a; Wang et al., 2011). While its underlying
etiology is not known, contributing factors may include
preleukemic donor cells, cytotoxic chemotherapy,
bystander radiation damage, defective BM microenviron-
ment, impaired immune surveillance, replicative stress,
viral and/or oncogene integration, and occult leukemia
in the donor (Wiseman, 2011). Collectively, these studies
demonstrate that DDL is a significant adverse event of an
important treatment option and that a better understand-
ing of its pathogenesis and risk factors will improve both
diagnosis and treatment.ports j Vol. 15 j 279–291 j August 11, 2020 j ª 2020 The Author(s). 279
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Represents a Novel Risk Factor for DDL
Clonal hematopoiesis of indeterminate potential (CHIP) is
characterized by the expansion of specific leukocyte clones
in healthy individuals (Jaiswal et al., 2014). As individuals
age, they accumulate somatic mutations in their HSPCs
that give rise to different blood cell lineages, including
monocytes, neutrophils, B cells, T cells, and megakaryo-
cytes. Thesemutations can endow a subpopulation of these
cells with a growth advantage (Jaiswal and Ebert, 2019). Us-
ing a variant allele frequency (VAF) of 2% or greater in
otherwise healthy individuals, the incidence of CHIP may
be as high as 95% depending on the method of detection
used, demonstrating that it may be quite common (Steen-
sma, 2018b; Young et al., 2016). The threemost commonly
mutated genes in CHIP are the epigenetic regulators Tet2
methycytosine dioxygenase 2 (TET2), DNA methyltransferase
3A (DNMT3A), and Associated sex combs-like 1 (ASXL1)
(Jaiswal et al., 2014). Importantly, CHIP is associated with
increased risks of hematological malignancy, cardiovascu-
lar disease (CVD), and all-cause mortality (Jaiswal et al.
2014, 2017). The presence of these preleukemic mutations
in donor BM cells may increase the potential for these cells
to undergo oncogenic transformation, suggesting that
CHIP may be an important risk factor for DDL if trans-
mitted to recipients.
CHIPmay contribute to altered transplant outcomes and
the development of DDL after both autologous and alloge-
neic HSCT (Table 1). Autologous transplantation can facil-
itate expansion of HSPC clones containing CHIP-associ-
ated mutations (Ortmann et al., 2019). These HSPCs
demonstrate long-term engraftment and reconstitute the
blood cell lineages. CHIP patients exhibited longer neutro-
phil reconstitution, longer periods of hospitalization, and
prolonged neutropenia. Clones carrying these preleukemic
mutations can be detected years before disease onset and
expand in response to transplantation (Berger et al.,
2018; Ortmann et al., 2019). The stress of transplantation
has been proposed to drive expansion of HSPCs containing
CHIP-associated mutations, implicating factors in the
transplant environment in the modulation of HSPCs con-
taining CHIP-associated mutations (Ortmann et al.,
2019). In patients who underwent autologous transplanta-
tion for lymphoma, CHIP correlated with inferior survival
and an increased risk of therapy-relatedmyeloid neoplasms
(TMNs) (Gibson et al., 2017b). Notably, patients carrying
more than one mutation at transplantation exhibited an
increased risk of TMN. In a similar study, decreased overall
survival was specifically observed in patients carrying
mutations in DNA repair pathway genes, such as protein
phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), tumor pro-
tein 53 (TP53), BRCA1/BRCA2-containing complex subunit 3
(BRCC3), and RAD21 cohesin complex component (RAD21)280 Stem Cell Reports j Vol. 15 j 279–291 j August 11, 2020(Husby et al., 2020). PPM1D can drive clonal hematopoiesis
(CH) in response to cytotoxic therapy, inferring a potential
role for external stressors in promoting clonal expansion
(Hsu et al., 2018). However, chemotherapy may not be
required, providing the opportunity for multiple contrib-
uting factors (Ortmann et al., 2019). Surprisingly, muta-
tions in other CHIP-associated genes, such as DNMT3A,
TET2, and ASXL1, were observed but were not associated
with inferior outcomes, implying that specific CHIP-associ-
ated mutations may be more susceptible to the autologous
transplant environment (Husby et al., 2020). Similarly, in
patients undergoing autologous transplantation for multi-
ple myeloma, CHIP correlated with decreased survival and
increased multiple myeloma progression, indicating that
CHIP canmodulate multiple types of hematological malig-
nancy (Mouhieddine et al., 2020). Autologous transplanta-
tion in CHIP patients is also associated with late non-
relapse mortality, demonstrating that CHIP-associated mu-
tations have diverse effects on transplant outcomes (Slavin
et al., 2019).
In allogeneic transplantation, CHIP also correlates with
altered transplant outcomes. Unexplained cytopenias
were observed in HSCT recipients of CHIP donors, demon-
strating that donor clones containing CHIP-associatedmu-
tations can be transmitted to transplant recipients and can
influence recipient blood cell populations (Gibson et al.,
2017a ). CH is commonly detected in both donors and re-
cipients, and these transmitted clones can expand in recip-
ients (Boettcher et al., 2020; Wong et al., 2020). The pres-
ence of unexplained cytopenias is more common in
recipients with older donors, consistent with a possible
role for CHIP in pathogenesis (Gibson et al., 2017a). While
cytopenias are observed in DDL cases, it is not known if
they contribute to DDL pathogenesis (Wang et al., 2011).
HSPCs from older CHIP donors can also increase the risk
of chronic graft-versus-host disease (cGVHD), a multi-sys-
tem inflammatory response that occurs about 100 days af-
ter transplant (Frick et al., 2019; MacDonald et al., 2017).
The longer latency of cGVHD is consistent with the later
presentation of DDL, compared with traditional relapse.
Surprisingly, CHIP-associated mutations of donor origin
also correlate with a reduced occurrence of relapse (Frick
et al., 2019). It was postulated that, due to their enhanced
growth advantage, HSPCs bearing CHIP-associated muta-
tions outcompete the residual leukemic HSPCs that can
cause traditional relapse. Indeed, cGVHDmay be inversely
related to the occurrence of primary disease relapse; howev-
er, it may also create an immunosuppressive environment
in which leukemia and other cancers can arise (Poonsom-
budlert et al., 2019; Rizzo et al., 2009).
Similarly, MDS, a clonal disorder characterized by BM
failure that frequently progresses to AML, may be an early
or intermediary phase in progression to DDL, suggesting
Table 1. Studies Reporting a Role for CHIP in the Outcomes of Both Autologous and Allogeneic HSCT
Study No. of Patients Donor/Recipient Ages Transplant Type DDL Cases Clinical Outcomes
Gondek et al. (2016) 61 donor/
recipient pairs
>60/43 and 26 years




2 Focal erythroid dysplasia,
myeloid blasts,
cytopenias, and MDS were
observed in DDL patients.











No cases reported 89 patients exhibited cytopenias
6 of which were unexplained.




1 The recipient developed
DDL, while the donor later
developed AML.
Frick et al. (2019) 500 donor/
recipient pairs




relapse correlated with CHIP.
DNMT3A mutations associated
with a decreased risk of relapse.
Gibson et al. (2017b) 401 patients 170 patients R60 years;
231 patients <60 years
autologous 18 cases of TMN Patients with CHIP exhibited an
increased risk of TMN, decreased
overall survival, and increased
mortality due to CVD.




mean age of 55.4 years
at graft collection









Boettcher et al. (2020) 45 donor/
recipient pairs
37/38 years initially;




1 MDS case Donor-engrafted
clonal hematopoiesis was detected
in 5 cases . O
ne case progressed to MDS.




No cases reported. Clonal expansion, but not
DDL, was observed during the
follow-up period.
Husby et al. (2020) 892 lymphoma
patients
R18 years autologous CHIP correlated
with an increased
risk of TMN.
Patients with mutations in













CHIP patients had worse
overall survival and
progression-free survival,
primarily due to progression
of multiple myeloma.
CHIP was not associated
with an increased risk of TMN.
CHIP, clonal hematopoiesis of indeterminate potential; TMN, therapy-related myeloid neoplasm; MDS, myelodysplastic syndrome; HSCT, hematopoietic stem
cell transplant; CVD, cardiovascular disease.
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sion (Sperling et al., 2017; Suarez-Gonzalez et al., 2018a;
Wiseman, 2011). MDS has been observed in up to 70% ofDDL cases, and CHIP-associated MDS after allogeneic
transplantation has been reported (Boettcher et al., 2020;
Schwartz et al., 2018; Wang et al., 2011). Loss of Asxl1 inStem Cell Reports j Vol. 15 j 279–291 j August 11, 2020 281
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tions are associatedwith inferior outcomes inMDS patients
undergoing HSCT, implicating CHIP-associated mutations
inMDS (Abdel-Wahab et al., 2013; Bejar et al., 2014). Germ-
line mutations, including those in GATA binding protein 2
(GATA2), DEAD-box helicase 41 (DDX41), CCAAT enhancer
binding protein alpha (CEBPA), and runt-related transcription
factor 1 (RUNX1), can also cause donor-derived AML and
MDS; however, the implications of CHIP in patients with
these germlinemutations has not yet been explored (Berger
et al., 2017; Galera et al., 2018; Owen et al., 2008; Xiao
et al., 2011). In particular, DDX41 mutations have been
observed in older DDL patients together with mutations
in CHIP-associated genes, providing an opportunity for in-
teractions between germline mutations and CHIP-associ-
ated mutations in DDL (Berger et al., 2017).
As clonal evolution and the acquisition of mutations
contribute to leukemogenesis, additional events may be
required to drive CHIP-mutant HSPCs toward DDL
(Leeksma et al., 2019; Sandén et al., 2020; Schaefer and
Lindsley, 2018). Patients withCHIP-associatedDDL exhibit
multiple mutations in blood cell lineages and complex
clonal compositions (Boettcher et al., 2020; Gondek
et al., 2016; Herold et al., 2017; Suarez-Gonzalez et al.,
2018b). The combinations of clones that arise and the spe-
cific mutations that they carry may influence their
leukemic potential (Wong et al., 2018). The presence of
additional mutations in clones originally containing
CHIP-associated mutations and the evolution of indepen-
dent clones with newmutations have been detected, high-
lighting the complexity of clonal evolution (Boettcher
et al., 2020). The combination of loss of Tet2with constitu-
tive activation of the fms related tyrosine kinase (Flt3) alters
the chronic myelomonoctyic leukemia- or myeloprolifera-
tive neoplasm-like phenotype characteristic of singlemuta-
tions to an AML-like phenotype (Ramdas et al., 2020; Shih
et al., 2015). This finding demonstrates that additionalmu-
tations can modify the disease presentation and may help
explain the heterogeneity observed in DDL. The presence
of both germline and somatic mutations may further
enhance clonal complexity in the context of DDL. The
clonal evolution of mutant HSPCs is also consistent with
the longer latency observed in DDL compared with tradi-
tional relapse, indicating that time is needed to acquire
these mutations. Consistent with the observation that
clones carrying CHIP-associated mutations may persist
for years before progressing to DDL, somatic mutations
can be present years before the diagnosis of AML (Desai
et al., 2018). Notably, in many of these studies, donor mu-
tations inDNMT3A are frequently transmitted to recipients
and contribute to cGVHD, clonal evolution, and DDL, sup-
porting a unique role for DNMT3A (Boettcher et al., 2020;
Frick et al., 2019; Gibson et al., 2017a; Gondek et al.,282 Stem Cell Reports j Vol. 15 j 279–291 j August 11, 20202016; Herold et al., 2017; Yasuda et al., 2014). CHIP-associ-
ated mutations in different genes may have differential
propensities to affect HSCT and promote DDL; however,
additional studies are needed. Collectively, these studies
suggest that CHIP-associated mutations of donor origin
can alter HSCT outcomes and may provide the context in
which DDL can develop. The ability of HSPCs carrying
CHIP-associated mutations to impair graft function indi-
cates a need for further studies to evaluate the incidence
of CHIP in transplant failure. cGVHD and MDS may be
intermediary stages in the development of DDL that can
progress through clonal evolution and may differ from
their traditional presentations in the context of CHIP (Fig-
ure 1). However, it is not known if CHIP-associated cGVHD
or MDS can progress to DDL and, if so, which factors pro-
mote this transition.
Both Cell-autonomous and Non-cell-autonomous
Factors May Contribute to DDL
The ‘‘seed and soil’’ hypothesis is an important concept in
DDL andmay be relevant in considering the role of CHIP in
DDL (Flynn and Kaufman, 2007). It highlights the poten-
tial contributions of both intrinsic and extrinsic factors to
leukemogenesis. One hypothesis regarding DDL pathogen-
esis is thatHSPCs acquire preleukemicmutations due to the
stresses of the transplantation environment (Flynn and
Kaufman, 2007; Wiseman, 2011). However, in CHIP,
HSPCs already carry preleukemic mutations and may be
primed to promote DDL. The ability of clones containing
CHIP-associated mutations to expand within the HSPC
population supports an inherent growth advantage for
these mutations. Cell-autonomous properties of HSPCs
bearing CHIP-associated mutations may depend on the
epigenetic state of these cells and may be retained under
stressful conditions, including transplantation, inflamma-
tion, and genotoxic stress, implicating intrinsic features
of HSPCs in clonal behavior during DDL (Yu et al., 2016).
The presence of germline mutations in donor HSPCs may
also endow these cells with cell-autonomous advantages.
CHIP-associated mutations in different epigenetic regu-
lators can bias the differentiation potential of HSPCs, lead-
ing to different clinical presentations (Xie et al., 2014).
Similarly, inactivation of Tet2 and Asxl1 in mice results in
myeloid pathologies, whereas loss of Dnmt3a causes both
lymphoid and myeloid disease patterns (Abdel-Wahab
et al., 2013; Li et al., 2011; Mayle et al., 2015). Conse-
quently, these mutations may influence the presentation
of DDL. In a cohort of CHIP patients, higher VAFs were de-
tected in granulocytes, monocytes, and natural killer cells,
compared with B and T cells, indicating a propensity for
CHIP-associated mutations in myeloid lineages (Arends
et al., 2018). However, in DDL patients, CHIP-associated
mutations are detected in both myeloid and lymphoid
Figure 1. cGVHD and MDS May Represent
Intermediary Stages in the Development
of DDL
Both HSPCs containing CHIP-associated mu-
tations and the aging, conditioned, and
leukemic BM microenvironment can cause
inflammation through the secretion of cyto-
kines and may lead to cGVHD or MDS. These
inflammatory states may facilitate expansion
of CHIP clones, acquisition of new mutations,
or changes in hematopoiesis that promote
DDL. Additional triggers (lightning bolt),
such as comorbidities, may also be needed to
progress to DDL. EC, endothelial cells; MC,
mesenchymal cells.
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HSPCs (Boettcher et al., 2020; Herold et al., 2017). Intrigu-
ingly, in a 7-year longitudinal study of a single patient, only
the myeloid lineage acquired additional mutations and
progressed to leukemia (Herold et al., 2017). Consistently,
most DDL cases cause AML; however, as DDL also includes
lymphoid leukemias, a distinct mechanism may exist for
the development of donor-derived lymphoid leukemias
(Suarez-Gonzalez et al., 2018a; Wiseman, 2011). It is not
yet known if CHIP contributes to both myeloid and
lymphoid presentations of DDL. Germline mutations,
such as those in RUNX1, are associated withmyeloidmalig-
nancies, and may, therefore, further bias HSPCs toward
myeloid lineages in DDL (Owen et al., 2008). As CHIP-asso-
ciated mutations are typically observed in older individ-
uals, intrinsic factors of aged HSPCs may also contribute
to skewing of differentiation toward myeloid lineages
(Mendelson and Frenette, 2014). In addition to influencing
expansion and differentiation, CHIP-associated mutations
can influence signaling in HSPCs and their progeny. For
example, loss of Tet2 andDnmt3a inmice promotes inflam-
mation (Cai et al., 2018; Cull et al., 2017; Leoni et al., 2017;
Zhang et al., 2015). The release of cytokines by Tet2-defi-cient HSPCs alters the frequencies of mesenchymal stem
cells, endothelial cells, and osteoblasts and may make the
BM microenvironment more conducive to DDL (Li et al.,
2018; Ramdas et al., 2020) (Figures 1 and 2). Together, these
studies demonstrate that HSPCs bearing CHIP-associated
mutations may intrinsically contribute to DDL pathogen-
esis via multiple mechanisms.
While preleukemic mutations can provide donor
HSPCs with cell-autonomous advantages and signaling
mechanisms, the BM microenvironment promotes
leukemogenesis via non-cell-autonomous mechanisms
that may also be relevant in DDL (Schepers et al.,
2015). Consisting of diverse cell populations, including
osteoblasts, mesenchymal cells, and endothelial cells,
the BM microenvironment provides signaling and
secreted factors that facilitate the engraftment of donor
HSPCs (Mendelson and Frenette, 2014). However, condi-
tioning regimens can radically alter the BM microenvi-
ronment, damaging the stromal cells and impairing their
ability to support hematopoiesis during recovery (Banfi
et al., 2001; Domenech et al., 1998). Significant changes
in the gene expression and DNA methylation of multi-
potent mesenchymal stromal cells and HSPCs areStem Cell Reports j Vol. 15 j 279–291 j August 11, 2020 283
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(Shipounova et al., 2017; Trino et al., 2019). The
potential role for methylation in the transplant BM
microenvironment is particularly compelling consid-
ering that DNMT3A mutations are frequently present
in CHIP-associated DDL.
Inflammation is also an important regulator of the BM
microenvironment during transplantation (Singh et al.,
2020). Interleukin-1b (IL-1b) is secreted by stromal cells
in response to irradiation and can modulate both mesen-
chymal cell proliferation and hematopoiesis (Bigildeev
et al. 2013, 2015). Importantly, its ability to regulate he-
matopoiesis may be context-dependent (de Haan et al.,
1993). Transplantation stresses may create an environ-
ment that selects for HSPCs bearing CHIP-associated mu-
tations from the transplanted BM. Consistent with this
notion, inflammation facilitates the expansion of Tet2-
deficient HSPCs (Abegunde et al., 2018; Cai et al., 2018).
In addition to conditioning, the BM microenvironment
in transplant patients has been exposed to hematological
malignancy and, therefore, may already be altered. For
example, AML can remodel the BM microenvironment
to support leukemic cells and suppress normal hematopoi-
esis (Baryawno et al., 2019; Kumar et al., 2018). The extent
of this remodeling may affect the likelihood of trans-
planted HSPCs bearing CHIP-associated mutations to
progress to DDL. Compared with primary hematological
malignancies associated with CHIP the transplantation
environment and previous exposure to hematological ma-
lignancy are unique stresses to HSPCs carrying CHIP-asso-
ciated mutations in DDL and may shape the potential of
the BM microenvironment and donor HSPCs to promote
DDL.
Age alters the BMmicroenvironment and may affect the
efficiency of HSCT in elderly patients (Ho et al., 2019; Ver-
ovskaya et al., 2019). Together with metabolic and epige-
netic shifts, the composition of supporting cells and the
levels of secreted factors in the BM microenvironment
change with age (Mendelson and Frenette, 2014; Verov-
skaya et al., 2019). Detected both systemically and in the
BM stroma, inflammation is an important event during ag-
ing and can alter hematopoiesis (Kovtonyuk et al., 2016;
Helbling et al., 2019). As inflammation can contribute to
cancer pathogenesis, one possible explanation for the
development of DDL fromCHIP donors is that hematopoi-
etic lineages exhibiting pro-inflammatory phenotypesmay
modify the BM microenvironment and hematopoiesis to
promote leukemogenesis (Figure 2) (Henry et al., 2015;
Leimkuhler and Schneider, 2019). For example, chronic
exposure to IL-1 reduces HSPC self-renewal capacity, skews
differentiation towardmyeloid lineages, hinders transplan-
tation, and contributes to hematological malignancy (Pie-
tras et al., 2016; Arranz et al., 2017). As cytokines regulate284 Stem Cell Reports j Vol. 15 j 279–291 j August 11, 2020hematopoiesis, the perturbation of cytokine signaling asso-
ciated with CHIP-associated HSPCs, transplantation, and
aging may alter the hematopoietic potential of the trans-
planted donor cells (Figure 2) (Mirantes et al., 2014).
Leukemic HSPCs exhibit higher self-renewal capacity
when transplanted in adultmice, comparedwith neonates,
suggesting that the aged BM microenvironment more
effectively promotes leukemogenesis (Lee et al., 2019). It
is unclear if the clinical presentation and pathogenesis of
DDL differ with age and the mechanisms by which HSPCs
bearing CHIP-associated mutations interact with the BM
microenvironments of different ages are not known
(Wang et al., 2011;Wiseman, 2011). Recently, CHIP-associ-
atedmutations were detected inmuch younger individuals
(Wong et al., 2020). With these younger individuals as do-
nors, efficient engraftment and expansion of clones
bearing CHIP-associated mutations were reported, but
DDL orGVHDwere not observed up to 100 days after trans-
plant. A longer latency, additional environmental factors,
or aged HSPCs may be needed to drive progression to
DDL or GVHD. The impact of and the mechanisms by
which the combined stresses of aging and transplantation
affect the BMmicroenvironment are not yet known. Trans-
plantation and HSPCs carrying CHIP-associated mutations
may further exacerbate and prolong age-associated inflam-
mation, and this process may support DDL pathogenesis
(Kovtonyuk et al., 2016).
Inflammation in the BM microenvironment can also
cause DNA damage, which may drive the acquisition of
additional mutations that can promote DDL (Wiseman,
2011; Leimkuhler and Schneider, 2019). Inflammation in
BM stromal cells exacerbates genotoxic stress and promotes
progression of preleukemic conditions (Zambetti et al.,
2016). HSPCs carrying CHIP-associated mutations may be
more susceptible to the acquisition of newmutations, facil-
itating the clonal evolution needed to progress to DDL (Pan
et al., 2017). Seventy-two percent of DDL cases exhibit
abnormal karyotypes, and CHIP donors and their recipi-
ents have shorter telomeres, supporting a role for genotoxic
stress in CHIP-associated DDL (Boettcher et al., 2020;
Suarez-Gonzalez et al., 2018a). As inflammation contrib-
utes to both cGVHD and MDS, these inflammatory states
may provide the necessary stresses to drive the acquisition
of additional mutations and transformation to DDL (Fig-
ure 1) (MacDonald et al., 2017; Sallman and List, 2019).
The aging BM microenvironment also exhibits increased
levels of reactive oxygen species, which can cause geno-
toxic stress in HSPCs (Verovskaya et al., 2019). Further-
more, in cases of CHIP-associated TMN, mutations in
TP53 and PPM1D, key regulators in DNA damage repair,
are prominent and can cause clonal expansion (Chen
et al., 2019; Gibson et al., 2017b). As germline mutations
are associated with MDS and AML, the presence of these
Figure 2. Models for the CellAutonomous
and Non-cell-autonomous Factors that
May Promote CHIP-Associated DDL
(A) In a cell-autonomous context, HSPCs
carrying CHIP-associated mutations may
release cytokines that can remodel the BM
microenvironment to promote the develop-
ment of DDL by altering normal hematopoie-
sis, by facilitating the expansion of CHIP
clones, and/or by driving the acquisition of
new mutations.
(B) In a non-cell-autonomous scenario, the
aged, conditioned, or leukemic BM microen-
vironment of the recipient can secrete cyto-
kines to promote the expansion of donor
HSPCs containing CHIP-associated muta-
tions, the acquisition of new mutations, and/
or the disruption of normal hematopoiesis,
which may lead to DDL. EC, endothelial cells;
MC, mesenchymal cells.
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create an environment conducive to DDL (Kobayashi et al.,
2017).
Likely, a combination of cell-autonomous and non-cell-
autonomous factors is involved in DDL pathogenesis,
and additional studies are needed to elucidate the impor-
tance of these factors in disease progression (Figure 2). In-
flammatory signals may originate from HSPCs bearing
CHIP-associated mutations, from the aged transplant BM
microenvironment, or both, and significant communica-
tion may occur between the CHIP-mutant HSPCs and the
BM microenvironment. These inflammatory signals may
lead to cGVHD, MDS, and/or DDL. Our group recently
showed that preleukemic Tet2-deficient HSPCs can modu-
late the BM microenvironment via pro-inflammatory
factors and that these cells cause myeloproliferative neo-
plasms when transplanted into a leukemic environment
(Ramdas et al., 2020). These findings demonstrate that
the HSPCs carrying CHIP-associated mutations and the
BM microenvironment may act in concert to drive DDL.
In further support of the role of the BM microenviron-
ment, not all predisposed individuals develop CHIP-associ-
ated malignancy (Boettcher et al., 2020; Gondek et al.,
2016; Wiseman, 2011). For example, a recipient can
developDDL, while the donor does not exhibit hematolog-
ical malignancy, inferring that the recipients’ BMmicroen-vironment may stimulate HSPCs with CHIP-associated
mutations to promote DDL. Alternatively, the donor and
the recipient can present with different hematological ma-
lignancies and clinical outcomes. In 73 donor-recipient
pairs in which the recipients developed DDL, 85% of the
donors remained healthy, while 12% and 3% exhibited
hematological malignancies and non-hematologic can-
cers, respectively (Suarez-Gonzalez et al., 2018a). Consis-
tent with the relatively low risk of developing CHIP-associ-
ated hematological malignancies, this study indicates that
most donors do not develop cancer (Steensma, 2018a).
However, two distinct leukemias with different clinical out-
comes arose in a related donor-recipient pair followed over
time (Herold et al., 2017). This case shows that despite the
presence of common initial mutations, additional factors
unique to each patient may modulate the evolution and
presentation of leukemia.
As CHIP ismodulated by comorbidities, other conditions
may influence DDL and may account for differences in
clinical presentation between donors and recipients (Drag-
oljevic et al., 2018; Zhang et al., 2019). In addition,
different hematopoietic stressors may exert distinct effects
on the expansion of clones carrying specific CHIP-associ-
ated mutations (Wong et al., 2018). The wide variety of po-
tential stresses present in elderly patient populations may
be responsible for the significant heterogeneity observedStem Cell Reports j Vol. 15 j 279–291 j August 11, 2020 285
Figure 3. HSPCs Carrying CHIP-Associated Mutations Can Lead
to Different Outcomes in Donors and Recipients
In both scenarios, mutant HSPCs can either maintain the size of the
mutant clones (red) or these clones can expand. In donors, the
expansion of CHIP clones can lead either to CVD or the acquisition
of additional mutations (green). In recipients, the expansion of
CHIP clones can lead to the acquisition of additional mutations,
MDS, cGVHD, or the development of CVD. The acquisition of addi-
tional mutations likely requires a stressful event (lightning bolt) to
drive mutagenesis. It is unclear whether CHIP-associated MDS and
cGVHD can progress to DDL and whether additional mutations are
needed.
Stem Cell Reports
Reviewin DDL patients (Figure 3). Inferior outcomes have been
observed in elderly patients with comorbidities that un-
dergo HSCT; however, it is not known if DDL and CHIP
are more common in these patients (He et al., 2017; Muffly
et al., 2017). These triggers imply that the causative factors
of DDL may be more diverse than previously thought and
that DDL should be considered in broader contexts
clinically.
The Role of CHIP in DDL May Expand the Clinical
Scope ofDDL to Include SolidOrganTransplants, Non-
hematologic Cancers, and CVD
As new causative and modulatory factors for DDL are being
discovered, it may present in a variety of ways clinically. In
addition toHSCT,DDLhas been reported in cases of solid or-
gan transplants (Bodo et al., 1999; Girsberger et al., 2013;
Subkleweetal., 2004).A57-year-oldwomandevelopedacute
promyelocytic leukemia 2 years after receiving a liver trans-
plant from a 16-year-old boy (Bodo et al., 1999). AML was
observed in a 43-year-oldman 3 years after a liver transplant286 Stem Cell Reports j Vol. 15 j 279–291 j August 11, 2020and in a 69-year-old kidney transplant recipient 2 years post-
transplant (Girsberger et al., 2013; Subklewe et al., 2004).
Notably, in the latter case, the donor was an 81-year-old
woman with an unremarkable medical history. As in DDL
due to HSCT, these cases exhibited long latencies to the
development of leukemia, but it is not known if CHIP con-
tributes to thesemanifestationsofDDL.Significantly, thepa-
tients in these cases succumbed to their diseases, indicating
that DDL from solid organ transplants is also severe (Bodo
et al., 1999; Girsberger et al., 2013; Subklewe et al., 2004).
The manifestation of DDL in these cases is particularly
remarkable because the organs transplanted were not typi-
cally hematologic organs in adults, suggesting that other
mechanisms may be involved in DDL. While the possible
contribution of CHIP to DDL in solid organ transplants has
not yet been investigated, the occurrence of DDL from solid
organ transplants raises concerns about screening for CHIP
in solid organ donors in addition to HSCT.
The identification of TMNs in CHIP patients undergoing
autologous transplantation for lymphoma indicates that
HSPCscontainingCHIP-associatedmutationsmaybepartic-
ularly susceptible to cancer treatments and other environ-
mental stresses (Gibson et al., 2017b; Husby et al., 2020).
However,CHIP is also commonlydetected incancerpatients
before treatment and can predispose patients with non-he-
matologic cancers to the development of TMNs (Arends
et al., 2018;Gillis et al., 2017; Takahashi et al., 2017). Patients
with solid cancers undergoing treatment exhibited VAF
changes of at least 50%, further supporting the sensitivity
of hematopoietic cells bearing CHIP-associated mutations
to external stresses (Arends et al., 2018). In addition, depend-
ing on the gene mutated, some patients needed more
frequent blood cell transfusions and dose reductions, identi-
fying a role for CHIP in guiding the treatment of non-hema-
tologic cancers. These studies suggest that elderly cancer pa-
tients receiving treatment may be at an increased risk of
developing DDL or other CHIP-associated conditions, espe-
cially if they have other comorbidities. Additional studies
are needed to better understand these potential risk factors.
These studies support a more expansive evaluation of CHIP
in cancer patients generally.
While the risk of developing hematologic malignancies
fromCHIP is 0.5%–1%, there is amuch greater risk of devel-
oping CVD (Dorsheimer et al., 2019; Jaiswal et al., 2017;
Steensma, 2018a). Notably, CVD is also a significant
morbidity in HSCT patients (Armenian et al., 2017). As in
CHIP, HSCT patients exhibit heart failure and coronary
artery disease; however, the mechanisms underlying this
presentation are not known (Armenian et al., 2018). In a
model of Tet2 deficiency in atherosclerosis-prone low-
density lipoprotein receptor-deficient mice, macrophages
secreting IL-1b exacerbate atherosclerosis (Fuster et al.,
2017). An increased risk of mortality due to CVD was
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plantation for lymphoma, inferring a possible role for
CHIP in transplant-associated CVD (Armenian et al.,
2017). Importantly, it is not known if CHIP increases the
risk of CVD in DDL patients and if the presence of CHIP
in an HSCT donor or recipient directly contributes to
CVD. However, fewer CHIP-mutant cells may be required
to promote CVD than hematological malignancy, high-
lighting the importance of evaluating CVD in HSCT pa-
tients and in patients with CHIP-associated DDL. Addi-
tional studies are needed to investigate these possibilities.
Nonetheless, these studies infer a potential link between
the hematopoietic and cardiovascular systems that may
have significant implications for pathogenesis and the
treatment of HSCT and DDL patients.
Collectively, these different clinical manifestations of
DDL underscore a need to broaden the clinical approach
to these patients both in diagnosis and treatment. A better
understanding of the potentially diverse clinical presenta-
tions of these patients will facilitate their identification
and proper diagnosis at earlier stages and promote the
development of novel therapeutics.
CHIP Has Significant Implications for DDL
The potential of CHIP to contribute to DDL may also be a
concernwith other cell-based products, such as chimeric an-
tigen receptor T cells and donor lymphocyte infusions
(DLIs); however, more information is needed. With DLIs,
the composition of both donor and recipient HSPC clones
may evolve over time and respond to different stimuli,
altering the factors influencing DDL pathogenesis. CHIP-
associated inflammation may also have clinical implica-
tions. Our grouphas shown that inhibitionof inflammation
using the small-molecule APX3330 blocks clonal expansion
of Tet2-deficient HSPCs (Cai et al., 2018). However, it is also
important to understand the effects of anti-inflammatory
agents on the BM microenvironment as both HSPCs and
the BMmicroenvironment may be sources of inflammatory
signals in CHIP-associated DDL.
Currently, screening of donors for CHIP is controversial
(DeZern and Gondek, 2020; Gibson and Lindsley, 2020).
Screening for donors with CHIP before transplantation
may prevent adverse effects in HSCT patients as seemingly
healthy individuals may harbor growth-promoting muta-
tions in their HSPCs. However, challenges exist in the abil-
ity to effectively screen for all possible CHIP-associatedmu-
tations. As improved technologies facilitate the detection
of CHIP at lower VAFs, the elucidation of a pathogenic
threshold and its clinical significance are complex. The bio-
logical context of these mutations in the recipient and the
influences of comorbidities may govern their behavior and
clinical relevance. Screening for germline mutations is rec-
ommended to avoid related donors in these cases (Galeraet al., 2018; Kobayashi et al., 2017). While the conse-
quences of germline mutations for CHIP-associated DDL
are not yet known, future studies are needed to understand
the implications of these mutations and cancer predisposi-
tion syndromes, such as neurofibromatosis, Bloom syn-
drome, Fanconi anemia, and Li-Fraumeni syndrome, for
CHIP-associated DDL (Wiseman, 2011). In addition, the
status of CH in the donor can evolve over time, supporting
long-term follow-up of both donors and recipients. It also is
not known if there are CHIP-independent mechanisms of
DDL and if there are differences in clinical presentation,
mutations, and prognosis in patients with CHIP-associated
DDL, compared with DDL that is independent of CHIP. Ul-
timately, further studies are needed to understand the
effectiveness of donor screening.Conclusions
CHIP is a relatively common novel condition in elderly in-
dividuals andmay be an important risk factor for the devel-
opment of DDL, a significant complication of HSCT. The
more frequent use of HSCT in older populations is particu-
larly concerning as CHIP-associated mutations are
frequently observed in individuals older than 65 years
and increase with age. Recent studies suggest that CHIP
may adversely affect transplant outcomes and promote
DDL; however, many unanswered questions remain.
CHIPmay contribute to DDL pathogenesis via cell-autono-
mous and non-cell-autonomous mechanisms and may
lead to novel presentations of donor-derived disease, such
as CVD. A better understanding of the contributions of
CHIP to DDL will provide important knowledge about
the mechanisms of leukemogenesis and will have signifi-
cant implications for the diagnosis, treatment, and the
development of novel therapies for DDL.
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